Philips Slumps After Another Blow to US Sleep Devices Recall
- US regulator says more tests on recalled devices needed
- Device sales ban in US becoming more likely: Bernstein
This article is for subscribers only.
Royal Philips NV suffered another setback as the US drug regulator requested additional tests on its sleep apnea devices, warning that the company’s analysis of the recalled products is inadequate.
Further testing is required to “fully evaluate the risks” after initial results showed exposure to the devices is unlikely to cause considerable health damage to patients, the US Food and Drug Administration said in a statement on Thursday. The Dutch company’s shares fell as much as 10% in Amsterdam, the most in a year.